Sulphasalazine (SASP) is an immunomodulatory compound with disease-modifying activity in ulcerative colitis and in other autoimmune disorders. SASP was previously shown to prolong the survival of heart allografts in rats treated with cyclosporin A (CyA) for 9 days after transplantation. We have now
The enhancing effect of cyclosporine A and sulfasalazine on the prevention of rejection in rat cardiac allografts
β Scribed by Alkwin Wanders; Gunnar Tufveson; Bengt Gerdin
- Publisher
- Springer
- Year
- 1988
- Tongue
- English
- Weight
- 226 KB
- Volume
- 1
- Category
- Article
- ISSN
- 0934-0874
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The effect of rapamycin (RAPA) and cyclosporine A (CsA) monotherapy and combination therapy was examined in prevention of kidney allograft rejection in the mouse. Both drugs were administered orally for up to 14 days in BALB/c (H-2 d ) to C57BL/6 (H-2 b ) mice strong combination. Six groups were tre
As a first step to study the correlation of cardiac and skeletal muscle allograft rejection, we describe a new experimental rat model of simultaneous heterotopic heart and cutaneous maximus muscle flap allotransplant. Brown Norway rats were used as donors and Lewis rats as recipients. No immunosuppr
The present study assessed the effectiveness of cyclosporine (CSA) and subtotal marrow irradiation (TL1) alone, and CSA in combination with TL1 in a primate segmental pancreatic allotransplantation model. Continous administration of CSA 25 mg/kg/day and 50 mg/kg/day resulted in mean graft survival o